Hot Asian Stocks To Invest In Right Now

Stocks were lower in morning trading Wednesday as investors struggle to push Wall Street's record-setting rally into a fifth straight day.

The Standard & Poor's 500, which set a record closing high of 1,911.91 the day before, was down 0.2% to 1,908. The broad-based index bounced in and out of positive and negative territory earlier and managed to hit a new intraday record high of 1,913.62.

The Dow Jones industrial average was down 0.3% to 16,625 and the Nasdaq composite index dropped 0.4% to 4,221.

STOCKS: USA TODAY's live markets blog

The yield on the 10-year Treasury note sank to a new low for the year, falling to 2.46% from 2.52% late Tuesday.

Asian markets rose as Japan's Nikkei index gained 0.2% to 14,670.95. Hong Kong's Hang Seng index jumped 0.6% to 23,080.03.

Best Gold Stocks To Own For 2016: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Jayson Derrick]

  The FDA issued a statement related to Sarepta Therpaeutics (NASDAQ: SRPT) eteplirsen drug, noting that that the methods used in the study were not “adequately robust to support an NDA submission” and that it provided the company with recommendations on how to improve its analysis.” Shares gained 2.80 percent, closing at $16.17.

• [By Selena Maranjian]

  The biggest new holdings are Liberty Media�and the iShares MSCI Mexico Capped Investable Market Index Fund ETF. Other new holdings of interest include Sarepta Therapeutics (NASDAQ: SRPT  ) . Sarepta stock has soared about ninefold over the past year, and some still see it as undervalued. After Sarepta petitioned the FDA for accelerated approval for its Duchenne muscular dystrophy drug, eteplirsen, the FDA requested more information. That sent shares lower, but management is optimistic about its recent interactions with the FDA.

• [By Sean Williams]

  Today, we're going to take a closer look at�Sarepta Therapeutics' (NASDAQ: SRPT  ) presentation, which was delivered Wednesday by President and CEO Chris Garabedian.

Hot Asian Stocks To Invest In Right Now: Golden Minerals Co (AUM)

Golden Minerals Company (Golden Minerals), incorporated March 6, 2009, is a mining company. The Company owns and operates the Velardena and Chicago precious metals mining operations (the Velardena Operations) in the State of Durango, Mexico, the El Quevar advanced exploration property in the province of Salta, Argentina, and a diversified portfolio of precious metals and other mineral exploration properties located in the regions of Mexico and South America.

Velardena Operations

The Velardena Operations consists of two underground mines and two processing plants within the Velardena mining district, which is located in the municipality of Cuencame, in the northeast quadrant of the State of Durango, Mexico, approximately 65 kilometers southwest of the city of Torreon, Coahuila and approximately 140 kilometers northeast of the city of Durango, the capital of the State of Durango. Of the two underground mines consisting the Velardena Operations, the Velardena mine includes three different vein systems, including the Santa Juana, San Juanes and San Mateo systems. The second mine, the Chicago mine, is a producing mine located on the Chicago property approximately two kilometers south of the Velardena property.

The Company owns a 300 ton-per-day flotation sulfide mill situated near the town of Velardena. The mill has fully operational lead, zinc, and pyrite flotation circuits which produce lead, zinc and pyrite concentrates from the sulfide ore. The Company also own a conventional 550 ton-per-day cyanide leach oxide mill with a Merrill Crowe precipitation circuit and new installed flotation circuit, which is located adjacent to its Chicago mine. The mill is used to process oxide and mixed sulfide/oxide material from the Velardena Operations.

El Quevar

The Company's El Quevar silver project is located in the San Antonio de los Cobres municipality, Salta Province, in the altiplano region of northwestern Argentina, approximately 300 kilometers by! road northwest of the city of Salta, the capital city of the province. The El Quevar project is located near Nevado Peak with altitudes at the concessions ranging from 3,800 to 6,130 meters above sea level. The El Quevar project is consists of 32 exploitation concessions. The Company holds 31 of the concessions directly, and the Company controls the Nevado I concession, located approximately four kilometers from the Yaxtche target.

Zacatecas (Mexico)

The Zacatecas Mining District is located in the central part of Mexico, in the Faja de Plata mineral belt. The Company's Zacatecas project surrounds the municipalities of Zacatecas, Veta Grande, Guadalupe, Panuco, and Morelos in the state of Zacatecas, Mexico. The Company owns approximately 195 concessions totaling approximately 8,600 hectares in the Zacatecas project.

San Diego (Mexico)

The San Diego property, located in the State of Durango, Mexico, is situated approximately nine kilometers northeast of the Velardena property and contains the La Cruz-La Rata and El Trovador mines as well as a number of other shallower shafts which were sunk on narrower veins such as the Cantarranas, Montanez and El Jal. During the year ended December 31, 2012, a Phase VI drilling program was completed, which included five drill holes totaling 5,500 meters.

Advisors' Opinion:

• [By Joshi Madhavi]

  The company gets its revenues from two types of fees: management fees which are linked to the assets under management (AUM) and performance fees which can be quite volatile. Over the last five years AUM have increased by around 4% per annum from the low at the end of 2008. However, revenues have decreased by around 7% per annum. Performance fees have held up okay since 2008, but management fees have taken a big hit. Since revenues are dependent on the average AUM over the whole year, let�� look at revenues from 2009 ��they have grown by around 6.5% per annum in this case. Institutional clients are more sticky and stable compared to retail, but the company has not managed to increase AUM from this source substantially over the last five years.

Hot Asian Stocks To Invest In Right Now: China North East Petroleum Holdings Limited(NEP)

China North East Petroleum Holdings Limited engages in the exploration and production of crude oil in northern China. As of December 31, 2010, it operated 295 producing wells with proven reserves of 5,476,200 barrels of crude oil at Qian?an 112, Hetingbao 301, Daan 34, and Gudian 31 oilfields. The company, through its subsidiary, Song Yuan Tiancheng Drilling Engineering Co., Ltd., provides contract land drilling and other oilfield services for state-owned and non-state-owned oil companies. China North East Petroleum Holdings Limited is headquartered in Song Yuan City, the People?s Republic of China.

Advisors' Opinion:

• [By Robert Rapier]

  Another YieldCo,�Nextera Energy Partners�(NYSE: NEP) which will own and operate renewable energy plants built by�NextEra Energy�(NYSE: NEE) launched June 27. NEP priced its IPO at $25 per share, then saw the share price surge to $32.36 on the first day of trading. NEP�� initial portfolio will consist of wind and solar farms in the US and Canada with a total generating capacity just under a gigawatt.

• [By David Dittman]

  Question: Dave, any thoughts on NextEra Energy Partners LP (NYSE: NEP)? And, if you can build on that, maybe talk about how to approach an initial public offering (IPO) in general. Thanks.

• [By Ben Levisohn]

  Krishna and Krauklis note that Buffalo Wild Wings, Nextera Energy (NEP), Rexnord Corp (RXN), and The Advisory Board (ABCO) should benefit from recent acquisitions that should boost revenue growth, while�Buffalo Wild Wings and Cavium (CAVM) should see improvements thanks to the adoption of new technology that will help boost margins. Terex, The Advisory Board, and�Rexnord should get a boost from cost cutting, Krishna and Krauklis say.

Hot Asian Stocks To Invest In Right Now: Chatham Lodging Trust (REIT)

Chatham Lodging Trust is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It primarily invests in premium-branded upscale extended-stay and select-service hotels to create its portfolio. Chatham Lodging Trust was founded on October 26, 2009 and is based in Palm Beach, Florida.

Advisors' Opinion:

• [By GURUFOCUS]

  LTC Properties Inc. (LTC) operates as a health care real estate investment trust (REIT) in the United States.Yield: 5.2%

  Gladstone Commercial Corporation (GOOD) operates as a real estate investment trust (REIT) in the United States.Yield: 7.9%

• [By Dividends4Life]

  Host Hotels & Resorts Inc. (HST) is a publicly owned real estate investment trust (REIT). The firm primarily engages in the ownership and operation of hotel properties. Sept. 16, the company increased its quarterly dividend 9.1% to $0.12 per share. The dividend is payable on Oct. 15, 2013, to stockholders of record on Sept. 30, 2013. The yield based on the new payout is 2.6%.

Hot Asian Stocks To Invest In Right Now: HeartWare International Inc (HTWR)

Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.

Proprietary Pump Technology

The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of

blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.

The HeartWare System

The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.

The HeartWare MVAD

The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.

The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.

Advisors' Opinion:

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  HeartWare International Inc.(HTWR) said it received a warning letter from the U.S. Food and Drug Administration, citing concerns about procedures for validating device design and other issues.

• [By Todd Campbell]

  Competing for heart pump market share
  Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR  ) and Heartware (NASDAQ: HTWR  ) target the intermediate- and long-term-use market instead.

• [By Lauren Pollock]

  Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.

  Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.